- Home
- LTM vs JAZZ Comparison
LTM vs JAZZ Comparison
Compare LTM & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTM
- JAZZ
- Stock Information
- Founded
- LTM 1929
- JAZZ 2003
- Country
- LTM Chile
- JAZZ Ireland
- Employees
- LTM N/A
- JAZZ N/A
- Industry
- LTM
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- LTM
- JAZZ Health Care
- Exchange
- LTM NYSE
- JAZZ Nasdaq
- Market Cap
- LTM 9.5B
- JAZZ 8.4B
- IPO Year
- LTM N/A
- JAZZ 2007
- Fundamental
- Price
- LTM $31.13
- JAZZ $124.99
- Analyst Decision
- LTM Strong Buy
- JAZZ Strong Buy
- Analyst Count
- LTM 3
- JAZZ 13
- Target Price
- LTM $38.00
- JAZZ $187.15
- AVG Volume (30 Days)
- LTM 484.5K
- JAZZ 1.3M
- Earning Date
- LTM 01-01-0001
- JAZZ 04-30-2025
- Dividend Yield
- LTM 1.47%
- JAZZ N/A
- EPS Growth
- LTM 67.98
- JAZZ 41.75
- EPS
- LTM 0.00
- JAZZ 8.65
- Revenue
- LTM $12,833,043,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- LTM $9.30
- JAZZ $7.55
- Revenue Next Year
- LTM $4.48
- JAZZ $3.52
- P/E Ratio
- LTM $9.67
- JAZZ $14.45
- Revenue Growth
- LTM 10.24
- JAZZ 6.12
- 52 Week Low
- LTM $21.83
- JAZZ $99.06
- 52 Week High
- LTM $33.50
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- LTM N/A
- JAZZ 36.63
- Support Level
- LTM N/A
- JAZZ $120.61
- Resistance Level
- LTM N/A
- JAZZ $142.64
- Average True Range (ATR)
- LTM 0.00
- JAZZ 3.98
- MACD
- LTM 0.00
- JAZZ -2.17
- Stochastic Oscillator
- LTM 0.00
- JAZZ 19.88
About LTM LATAM AIRLINES GROUP SA SPON ADS EACH REP 2000 SHS
LATAM Airlines Group SA operates as a passenger airline group. Geographically, the company operates in Brazil, Chile, Colombia, Ecuador, and Peru, along with international operations within Latin America and to Europe, the US, and the Caribbean. The firm generates its revenue from transporting passengers and cargo.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.